长期外源性睾酮使用的跨性别男性子宫内膜癌
一例33岁跨性别男性在长期外源性睾酮治疗医疗性别转换期间发现IV期子宫内膜样腺癌,肿瘤雄激素受体阴性,行手术切除控制症状并接受姑息化疗,多学科讨论继续睾酮治疗的风险与获益后术后重启睾酮治疗。
要点
- 跨性别男性激素治疗需监测,无月经者出现异常阴道出血应尽快评估。
- 长期雄激素使用对恶性肿瘤发生的影响可能未知。
- 跨性别男性生殖器官癌症治疗可能因希望继续雄激素治疗而复杂化。
核心结论
- 长期雄激素使用对恶性肿瘤发生的影响可能未知。
- 跨性别男性生殖器官癌症的治疗可能因希望继续雄激素治疗而复杂化。
研究设计与样本
- 个案报告:一例33岁跨性别男性,接受外源性睾酮治疗用于医疗性别转换。
主要发现
- 患者发现IV期子宫内膜样腺癌。
- 肿瘤雄激素受体阴性。
- 行手术切除以控制症状,并接受姑息化疗。
- 多学科讨论继续外源性睾酮治疗的风险与获益后,术后重启睾酮治疗。
关键数值与推荐
- 跨性别男性激素治疗需要监测。
- 对接受激素治疗的无月经跨性别男性个体,出现异常阴道出血应尽快评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone therapy (HT) in transgender males requires monitoring. For amenorrheic transmasculine individuals on HT, episodes of abnormal vaginal bleeding should be assessed promptly. CASE: A 33-year-old transgender man on exogenous testosterone therapy for medical gender transition was found to have stage IV endometrioid endometrial adenocarcinoma. Surgical resection was performed for symptom control, and the patient was treated with palliative chemotherapy. The tumor was androgen receptor-negative, and, after a multidisciplinary discussion of the risks and benefits of continuing exogenous testosterone, testosterone therapy was restarted postoperatively. CONCLUSION: Long-term androgen use may have unknown implications for the development of malignancy, and treating reproductive organ cancer in transgender males may be complicated by the desire to continue androgen therapy.
引用
- Gill S, Anderson M, Neveu J, et al. Endometrial Cancer in a Transgender Man with Prolonged Exogenous Testosterone Use. Obstet Gynecol. 2024. PMID: 38330401. doi:10.1097/AOG.0000000000005527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。